Startups Directory

Born inside the University of Evora, we are an R&D company dedicated to High Tech smart solutions for PV systems in particular and smart systems in general.

Control and monitoring of PV solar panels.

Contributing to Energy transition by best performance of PV panels.

1.000.000 euros

1.000.000 euros

We’re building certification-less space access giving 10x lower project cost & time. Our zero-gravity platform opens-up research in space for people that could never go before. Our first mission is sold out, with experiments in biotech, pharma, ISRU, and quantum computing.

Access to space.

By eliminating sedimentation, buoyancy, and convection, our platform enables breakthrough research for Earth-based industries, including biotech, pharmaceuticals, material science, and fundamental physics. We provide a unique environment to save millions of lives through advanced disease modelling, biofabrication & stem cell growth, and protein crystallisation. Also, by producing semiconductors and nanostructures in space, we can create essentially "perfect" materials that aren't possible on Earth. These advance our daily lives by making renewable energy more efficient, enabling faster connectivity with new 6G networks, and providing the massive processing power needed for next-generation AI.

0.5 M EUR

1.5 M EUR

WAPTEL (Wave and Particle Engineering Solutions) is a private fabless technology company based in Madrid that specializes in the design and development of high-tech photonic and electronic solutions, products, and services. Its capabilities span from concept and physical simulation of structures and devices to final system characterization, including manufacturing process definition and integrated circuit or structure design. The company conducts R&D in semiconductor technologies (especially III-V, lithium niobate and silicon), photonics, quantum devices, and wireless optical communications, and it possesses in-house prototyping facilities for advanced device development. WAPTEL’s work applies across consumer information and communication technologies as well as specialized areas such as aerospace, health, energy, security, and defense.

This technology addresses these main problems: • Limits of direct laser modulation at high speed • Costly/inefficient optical coupling in integrated waveguide modulators • Need for “natural” out-of-plane coupling in certain use cases • Possibility of using high-bandwith modulation for large area devices

This technology can improve high-speed optical communications while reducing energy consumption, enabling more efficient networks and data systems.

1 M€

The total size of the investment round is planned to be approximately 1M€.

Development of a new instrument to perform visual refraction more quickly and accurately than the conventional method.

Efficient access to high-quality visual refraction.

A paradigm shift in an evaluation method that has remained unchanged for over 200 years.

€350,000

€500,000

Repertor.IO is an innovative startup and academic spin-off of the Universities of Turin and Padua focused on making patient preferences usable in healthcare decision-making. Although Patient Preference Information is increasingly required by regulators such as EMA and FDA, it is still rarely used in practice due to fragmented evidence, methodological complexity, and time-consuming analyses. To address this gap we created Repertorio, the first and currently the only end-to-end platform specifically designed to overcome these barriers. By using AI-based methods to extract, structure, and synthesize patient preference data, and by performing advanced quantitative analyses, the platform delivers fast, reproducible, and decision-ready outputs. Repertorio enables pharma companies, regulators, HTA bodies, and researchers to systematically integrate the patient perspective across the medical product lifecycle, supporting the transition toward truly patient-centred care.

Repertorio addresses a critical gap in the use of Patient Preference Information across medical products and therapies: patient preferences exist, but they are rarely transformed into evidence that can be readily used in decision-making. Although regulators such as EMA and FDA increasingly encourage the inclusion of patient preferences, their practical use remains limited due to fragmented data, methodological complexity, and the lack of tools to aggregate, interpret, and integrate this information in a systematic way. In practice, generating usable evidence often requires manual, time-consuming analyses and static models that are difficult to update or reuse. Repertorio solves this problem by providing the first end-to-end, AI-native platform designed to turn patient preferences into decision-ready evidence. By automating data extraction, structuring, synthesis, and performing advanced meta-analysis, the platform delivers fast, reproducible outputs that can be directly integrated into development, regulatory, HTA, and clinical workflows. In this way, Repertorio enables the systematic use of patient preferences across the healthcare lifecycle, supporting the transition toward truly patient-centred care.

-Patients Repertorio helps ensure that new medical products and therapies reflect what patients truly value. Patient Preference Studies often show that patients and clinicians prioritize benefits, risks, and treatment burden differently, especially for innovative or high-risk therapies. By making patient preference evidence usable in practice, Repertorui supports more acceptable treatments, better shared decision-making, and improved adherence. -Regulators and public decision-makers EMA and FDA increasingly encourage the use of Patient Preference Information to support benefit–risk assessments, as demonstrated by recent regulatory decisions. At the same time, Health Technology Assessment (HTA) bodies and public payers are looking for robust patient-centred evidence to inform reimbursement, pricing, and coverage decisions. Repertorio enables transparent, reproducible, and patient-centred evidence to be systematically integrated into regulatory, HTA, and payer processes, improving the quality, consistency, and legitimacy of decision-making across the healthcare system. -Industry For pharmaceutical and life science companies, Repertorio enables more informed and patient-aligned development of medical products by translating patient preferences into actionable evidence. Integrating Patient Preference Information has been shown to increase expected net present value (≈ USD 35–70 million per project) and accelerate time to market ( by up to 2.5 years). Repertorio also helps reduce development costs by enabling a more efficient use and synthesis of existing patient preference evidence, avoiding redundant analyses and improving decision-making efficiency. Beyond efficiency gains, the platform supports the identification and profiling of patient segments with different preference patterns, informing product design, positioning, and market access strategies that better reflect real patient needs.

€500.000 for 2 years

€500000

GastroIntel is an AI based assistant designed to help professionals prepare for fairs and B2B events. It provides key information about companies and contacts, and helps start smarter conversations and find business opportunities more easily

Many professionals attend fairs without proper preparation. GastroIntel helps them understand companies and contacts better, start smarter conversations, and identify real business opportunities more efficiently.

GastroIntel helps professionals work more efficiently, reduce wasted time at events, and create better business connections. This leads to more meaningful collaboration and smarter use of knowledge and technology.

We are not raising investment at this stage

Not applicable. No investment round planned yet

Smart Scoliosis Developments SL is an innovative, technology-based startup dedicated to developing advanced solutions for the treatment of scoliosis, specifically adolescent idiopathic scoliosis (AIS).

Adolescent Idiopathic Scoliosis

Improving Current Outcomes in the Treatment of Adolescent Idiopathic Scoliosis

600.000€

1.200.000€

We are developing cutting-edge AI technology that enable industrial robots to autonomously perform waste‑sorting operations, significantly increasing throughput, operational efficiency, and worker safety in a critical link in the circular‑economy value chain.

Our technology addresses the heavy reliance on human labor in waste‑sorting plants. A job that is highly repetitive, physically demanding, and often hazardous due to noise, dust, and exposure to dangerous machinery. The sector also faces a persistent labor shortage, making it difficult to maintain efficient operations. By automating key sorting tasks with advanced AI‑driven robotics, we aim to reduce human exposure to unsafe conditions, improve overall plant productivity, and allow workers to focus on higher‑value activities.

Our technology will improve society by making waste‑sorting safer, more efficient, and more sustainable. By automating the most repetitive and hazardous tasks, we reduce workers’ exposure to unsafe conditions and allow them to focus on higher‑value activities. At the same time, greater sorting accuracy increases the recovery of secondary raw materials, strengthening the circular economy and reducing the amount of waste sent to landfills or incineration.

1.200.000,00 €

300.000,00 €

We are a deep technology research laboratory that develops advanced algorithms for solving complex problems, demonstrating the solution using virtual reality and mixed reality.

Visualization and diagnosis of heart disease without the use of invasive methods

Prevention in the diagnosis of heart disease. Savings for the National Health System of hundreds of millions of euros in cardiac mapping and navigation.

5 millions of euros

10 millions of euros

Juventas 4Life is dedicated to "delivering health to people through foods." We do research and develop new forms of food and supplements containing probiotics. Our probiotics do not require refrigeration to maintain their functionality and resist most industrial food manufacturing processes. They are supported by dozens of scientific studies, including clinical trials in humans. These properties allow us to develop a wide range of foods and beverages to reach the majority of the population (regardless of age) to strengthen people's overall health and well-being through the gut-microbiota-brain axis.

Our company develops a wide range of foods, beverages, and supplements with spore-forming probiotics (Bacillus subtilis natto DG101, of Japanese origin) to bring "greater health and well-being to people (of all ages) through nutrition." Spain has the highest life expectancy in Europe and the second highest in the world. Life expectancy in Spain exceeds 84 years (for both men and women), but healthy life expectancy, meaning without suffering from any illness (healthspan), does not exceed 60 years. This means that in Spain, as in any other region of Europe, people will spend their last 20 or 25 years of life suffering from some illness (stroke, cancer, diabetes, obesity, osteoporosis, Parkinson's, Alzheimer's). This is a reality that affects everyone, not only the elderly, but also children, adolescents, and young adults, since illnesses can appear at any point in life, from birth to old age. Our strategy to prevent diseases, that is, to improve people's quality of life, is through strengthening their gut microbiota ("second brain") with the consumption of spore probiotics (stable, safe and effective) that strengthen people's defenses and physical and mental health.

The impact will be to improve people's health and quality of life (healthspan), giving them the possibility of living more fully without getting sick (or getting sick less often). Precisely, our technology consists of offering different types of foods, drinks and supplements to people so that they have a wide and accessible range of options (to suit each person's taste and economic capacity) to strengthen their health and thus prevent the development of any type of disease.

No for the moment

No for the moment

Water treatment and water reuse using passive filtration concept.

Water scarcity

Medium impact

400k€

1M€

At Wavefront we are developing the next generation of stain-free, quantitative live-cell imaging solutions. Our computational microscope uses a patented technology that protects cell integrity unlocking unique cellular information. Wavefront is on a mission to develop an imaging technology that will go way beyond being just a tool for researchers. Our vision is to use our proprietary technology to build robust new clinical diagnostics systems that can analyze patient samples anywhere, faster and at a fraction of current costs.

Traditional microscopy techniques used for live-cell imaging are expensive and time- consuming and require sample preparation (staining) and the use of chemicals. These techniques are usually invasive, and cells can be affected by harshness and toxicity limiting its usability for further testing. The results obtained with invasive techniques are neither optimal nor efficient. Wavefront is developing an AI-enhanced computational microscope for live-cell imaging utilizing quantitative-phase-imaging (QPI) technology. Wavefront’s patented technology allows for non-invasive, stain-free imaging of live-cells, integrating AI to ensure high accuracy and real-time analysis.

Wavefront’s vision is to disrupt biomedical sciences and diagnostics by innovating cell imaging for a healthier world. Our technology has the potential to improve and automate medical diagnostics and other areas of biomedical sciences impacting positively on better and more affordable healthcare. In countries with a shortage of pathologists our solutions will provide a platform for remote diagnostics.

300.000€

300.000€

Biotech comany with a delivery system to help drugs reach the brain. First product in the field of pediatric brain tumors.

Improve the delivery of drugs to the brain a real bottleneck to cure CNS diseases.

1 every 4 of us suffer from a brain disease during our life.

10M€

10M€

SBS (Smart Brake Lighting System) is a patented automotive safety technology that introduces dynamic rear-light signaling during soft-braking scenarios, improving driver reaction time and reducing rear-end collisions. The system is fully aligned with the latest UNECE regulatory framework and protected by a strong global IP portfolio. SBS is designed for immediate OEM and Tier-1 integration, targeting 2026–2027 vehicle programs in Europe and globally.

SBS Smart Brake Lighting addresses a critical road-safety and communication gap in current rear-lighting systems. Conventional brake lights operate as a binary signal (on/off) and fail to convey gradual deceleration (soft braking), which represents the majority of real-world braking events. This limitation delays driver reaction, increases rear-end collision risk, and is particularly problematic in EV and ADAS-equipped vehicles where deceleration often occurs without strong brake pedal input. SBS solves this by: Enabling regulation-compliant dynamic rear-light signalling for soft braking Improving early perception of deceleration by following drivers Reducing reaction time and rear-end collisions Providing a globally patent-protected solution that OEMs and Tier-1 suppliers can deploy immediately for 2026–2027 vehicle programs The technology translates vehicle deceleration into intuitive visual cues, bridging the gap between vehicle dynamics, human perception, and the new UNECE regulatory framework.

SBS Smart Brake Lighting delivers a direct, measurable impact on road safety and societal well-being. Rear-end collisions are among the most frequent traffic accidents worldwide, causing injuries, congestion, and significant economic and social costs. A major contributing factor is delayed driver reaction due to insufficient communication of vehicle deceleration, especially during soft-braking events. By enabling earlier and more intuitive visual communication of deceleration: SBS reduces reaction times of following drivers Lowers rear-end collision risk, particularly in urban and high-traffic environments Improves safety for vulnerable road users by smoothing traffic flow and reducing sudden braking chains Supports the safe deployment of EVs and ADAS, where regenerative braking is often not clearly signaled At a systemic level, SBS: Aligns technology with new UNECE regulations, accelerating safer standards adoption Contributes to Vision Zero and road-safety policies Reduces societal costs related to accidents, healthcare, insurance claims, and traffic congestion In summary, SBS transforms rear lighting from a passive indicator into an active safety communication system, delivering benefits not only to drivers and OEMs, but to society as a whole.

We are seeking €1.5–2.0 million in this round. This is a strategic bridge round, not a long-term dilution round. The funds will be used to: Finalize regulatory, IP, and legal readiness post-UNECE WP.29 Support OEM and Tier-1 technical validations for 2026–2027 programs Strengthen our patent enforcement and transaction readiness (licensing / acquisition) Given the current stage — with regulatory approval achieved and Tier-1 acquisition discussions underway — this round is designed to maximize value and optionality, not to fund long product development cycles.

This round is structured as a bridge round to support final regulatory closure, IP strengthening, and strategic transaction execution with Tier-1 automotive suppliers.

We design new optical fiber sensor systems optimized for structural monitoring. We also offer monitoring engineering services, formation and advice for the industries.

We offer deep information about the structural condition in testing or operation of critical assets enabled by a novel technology that offers disruptive and diferential characteristics over stablished technologies. For instance, our solutions are interesting for civil infrastructures, precise tool machining, renewable energies, aerospace industry, among others.

A deeper knowledge about the structural condition of different elements, such as road condition, precise machine tooling of critical parts (plane engines...), stud bolts of an aerogenerator, etc. has important impact on the safety and security of the users and assets.

€300.000

€300.000